Ikarian Capital, LLC Bei Gene, Ltd. Put Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $47 Million - $58.9 Million	-160,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $16.5 Million - $24.1 Million	63,200 Added 64.95%	160,500 $55.9 Million
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $21.5 Million - $30.8 Million	97,300 New	97,300 $25.1 Million
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $9.38 Million - $13.3 Million	-77,000 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$115.78 - $208.34 $8.92 Million - $16 Million	77,000 New	77,000 $12.8 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.